^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TAVO412
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Tavotek
Drug class:
EGFR inhibitor, c-MET inhibitor, VEGF inhibitor
Related drugs:
Phase 1
Tavotek Biotherapeutics
Recruiting
Last update posted :
12/15/2023
Initiation :
05/08/2023
Primary completion :
06/30/2024
Completion :
12/01/2025
EGFR • MET
|
EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation
|
MP412 • TAVO412
Share
